TotipotentRX & ThermoGenesis Case Study Demonstrates Autologous Stem Cell
Product Safely Treats Primary Heart Attack in 60 Minute Clinical Procedure
Initial Data From AMIRST Combination Product Therapy 24 Month Safety Case
LOS ANGELES and RANCHO CORDOVA, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) --
TotipotentRX Corporation and ThermoGenesis Corp. (Nasdaq:KOOL), reported
yesterday at the annual meeting of the American Association of Blood Banks in
Denver, Colorado, a study confirming TotipotentRX's ground-breaking acute
myocardial infarction ("AMI") combination product utilizing ThermoGenesis'
point-of-care cell processing technology for an autologous bone marrow derived
stem cell therapy can be delivered safely in 60 minutes.
Mr. Ken Harris, Study Director and Chief Executive Officer of TotipotentRX,
presented a case study and physician feedback confirming that the Company's
Acute Myocardial Infarction Rapid Stem Cell Therapy ("AMIRST") protocol
utilizing autologous bone marrow derived stem cells achieved its primary
safety and secondary efficacy endpoints by improving the patient's Left
Ventricular Ejection Fraction ("LVEF") from 35% to 60.3% in 24 months while
preventing further infarct scarring and undesirable remodeling. Low LVEF and
heart remodeling are two key contributors in AMI patients advancing to heart
Dr. Ashok Seth, Chairman - Cardiac Sciences, and Dr. Vinay Sanghi, both of
Fortis Healthcare, conducted the clinical case study which shows the AMIRST
treatment safely delivered to a single male patient an effective dose of
autologous selected stem cells in a single intracoronary heart catheterization
procedure. The Company believes this is the first integrated combination
product treatment, consisting of a combination of devices and biologics, to be
evaluated in a larger follow-up study.
The combination product and procedure developed by TotipotentRX (patent
pending) incorporating ThermoGenesis' cell processing technology, is known as
the AMIRST protocol. The AMIRST protocol is performed by a cardiac
interventional physician in less than 60 minutes to treat acute ST-elevated
myocardial infarction in patients having an LVEF below 40%. This fully
integrated treatment includes:
*a stem cell friendly process for harvesting bone marrow derived stem cells
*an optimized stem cell dose preparation process (device & biological)
*a rapid bedside cell analysis system (dose verification)
*and a proprietary intracoronary catheter delivery method (device + method)
Dr. Vinay Sanghi, Clinical Investigator and treating physician on this case,
said "conducting a fully-integrated point-of-care treatment on a patient with
an acute ST-elevated myocardial infarction using the AMIRST protocol was
straightforward and very exciting as a practicing interventional
cardiologist.The safety and positive clinical benefits demonstrated in this
single patient case study are very encouraging as we begin the double-blinded
AMIRST study which should provide statistically significant insights".
Mr. Harris noted, "this case study affirmed that our integrated combination
product has appropriately considered the essential devices, diagnostics, cell
formulation, and directions for use ensuring the AMIRST treatment meets the
objectives of providing a safe, effective, rapid, bedside therapy for treating
low ejection fraction after a primary myocardial infarction." He continued,
"we are enthusiastically looking forward to the randomized placebo controlled
Phase Ib study in the coming few months.We envision this product, if
approved, will improve the quality of life and mortality rates of low LVEF
"We are very pleased with the initial results of this study using our
combination product," said Mr. Matthew Plavan, Chief Executive Officer of
ThermoGenesis. "In addition to the positive safety and efficacy data, we are
particularly encouraged by the potential durability of the treatment, given
this patient's LVEF exceeded 60% two years post treatment. Based upon the AMI
population and those that meet the criteria for an approved AMIRST therapy, we
estimate the addressable U.S. market for our combination product to exceed
$500 million per year."
This study will be advanced to a double blinded placebo-controlled randomized
Phase Ib clinical trial of 30 patients (NCT01536106) in the first quarter of
About Acute Myocardial Infarction
Cardiovascular disease ("CVD") is the number one cause of morbidity and
mortality worldwide.An estimated 17.3 million people died from CVDs in 2008,
representing 30% of all global deaths.Of these deaths 7.3 million were due to
coronary heart disease and 6.2 million from stroke.In the progression of
CVDs, plaque lesions develop in arteries that result in a narrowing of
vessels, and in severe cases the vulnerable plaque breaks open and creates a
blockage of blood flow to vital organs in the heart or brain.In the case of
the heart, this is classified as a myocardial infarction.LVEF is one of the
key indications of mortality rates post myocardial infarction with a reduced
LVEF being a risk factor for both sudden and non-sudden death, with the odds
ratio for 1 year mortality after myocardial infarction at 9.48 (High Rate) for
patients with an LVEF 30% compared to patients with LVEF > 50%, 2.94%
(Moderate Rate) for patients with LVEF 30-40%, whereas the risk is not
significantly increased (low rate) in patients with LVEF 40-50%.The specific
patient highlighted in this announcement was in the moderate risk category.
About TotipotentRX Corporation
TotipotentRX Corporation is engaged in the research, development, and
commercialization of cell-based therapeutics for use in regenerative medicine.
We provide products and services to patients, physicians and partners
including cell therapeutics, contract services, cell manufacturing and
banking, and medical devices for cell therapies.
The Company's lead therapeutic technology platform, TotiCell™ (an
intraoperative rapid system for harvesting, preparing, testing, and delivering
a therapeutic dose of autologous bone marrow derived or peripheral blood
derived cells and proteins), is currently in varying stages of Phase 1b trials
as a potential treatment for acute myocardial infarction, critical limb
ischemia, non-healing ulcers and avascular necrosis.
Our patented therapies are designed for rapid (under 60 minute) use at the
bedside and per U.S. regulations include all integrated equipment,
diagnostics, devices, and software to produce the specified autologous
therapeutic cell dose.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood and bone marrow processing systems and companion
disposable products that enable the separation, processing and preservation of
cell and tissue therapy products. These include:
*The BioArchive^® System, an automated cryogenic device, used by cord blood
stem cell banks in more than 30 countries for cryopreserving and archiving
cord blood stem cell units for transplant.
*AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
devices that includes the AXP and the MXP^® MarrowXpress^® and companion
sterile blood processing disposables for harvesting stem cells in closed
systems. The AXP device is used for the processing of cord blood. The MXP
is used for the preparation of cell concentrates, including stem cells
from bone marrow aspirates in the laboratory setting.
*The Res-Q^TM 60 (Res-Q), a point-of-care system designed for the
preparation of cell concentrates, including stem cells, from bone marrow
aspirates and whole blood for platelet rich plasma (PRP).
In July 2013, TotipotentRX and ThermoGenesis Corp. announced their entry into
a merger agreement which will operate under the name Cesca Therapeutics. The
merger is subject to TotipotentRx and ThermoGenesis stockholder approval,
among other conditions.
This press release and the information contained herein shall not constitute
an offer to sell, buy or exchange or the solicitation of an offer to sell, buy
or exchange any securities, nor shall there be any sale, purchase or exchange
of securities in any jurisdiction in which such offer, solicitation, sale,
purchase or exchange would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction.No offer of securities
shall be made except by means of a prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, as amended.
In connection with the merger, ThermoGenesis intends to file a registration
statement (including a prospectus) on Form S-4 with the Securities and
Exchange Commission.Holders of ThermoGenesis common stock and TotipotentRX
Corporation common stock are urged to read the proxy
statement/prospectus/consent solicitation and any other relevant documents
when filed because they contain important information about ThermoGenesis,
TotipotentRX and the merger.A proxy statement will be sent to holders of
ThermoGenesis common stock and a prospectus/consent solicitation will be sent
to holders of TotipotentRX Corporation common stock.When filed, the proxy
statement/prospectus/consent solicitation and other documents relating to the
proposed merger can be obtained free of charge from the SEC's website at
www.sec.gov. These documents can also be obtained free of charge from
ThermoGenesis upon written request to ThermoGenesis, Investor Relations, 2711
Citrus Road Rancho Cordova, CA 95742.ThermoGenesis and its directors and
executive officers may be deemed to be participants in ThermoGenesis'
solicitation of proxies from its shareholders in connection with the proposed
merger. Information regarding the participants and their security holdings can
be found in ThermoGenesis' most recent proxy statement filed with the SEC,
which are available from the SEC, and the proxy statement/prospectus/consent
solicitation when it is filed with the SEC.
CONTACT: ThermoGenesis Corp. Investor Relations
ThermoGenesis Corp. Logo
Press spacebar to pause and continue. Press esc to stop.